GLP-1 Digest

GLP-1 Digest

Home
Podcast
Archive
Leaderboard
About
🎧 Genetics Could Decide Who Wins the GLP-1 Market, Ep. 7 with 23andMe’s Dr. Adam Auton
Predicting weight loss and side effects before treatment begins
 • Ashwin Sharma, MD
53:20
🎧 Can Peptides Become a Real DTC Business? Ep.6 with Tim Gutwald
Before they become a real revenue stream, founders need to solve three unsexy problems
 • Ashwin Sharma, MD
58:47
🎧 GLP-1s Are Coming for the Snack Aisle, Ep. 5 with Henry Dimbleby
On shrinking food volumes, and why consumers want more value per bite
 • Ashwin Sharma, MD
53:37
What happens when GLP-1s go off-patent?
Five charts that’ve caught my eye
 • Ashwin Sharma, MD
🎧 Can GLP-1s Save the NHS? Ep. 4 with Lord James Bethell
Healthspan is decreasing in the UK, and the private market could help turn things around
 • Ashwin Sharma, MD
41:12
India is not the opportunity you think it is
Why DTC telehealth won't work in India's GLP-1 market
 • Ashwin Sharma, MD
🎧 Should GLP-1s be sold over the counter? Ep 3, with Dr. Beverly Tchang, MD
On the maintenance trap, microdosing for prevention, and frictionless access
 • Ashwin Sharma, MD
1:19:22
GLP-1 Digest
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Recommendations
View all 6
Big Pharma Sharma
Big Pharma Sharma
Big Pharma Sharma
The Device Files: From Concept to Commercialization
The Device Files: From Concept to Commercialization
Blythe Karow
The Gut Group
The Gut Group
Dr Arif Hussenbux MBBS
The Argument
The Argument
The Argument
In-Network
In-Network
David Ohta

GLP-1 Digest

AboutArchiveRecommendationsSitemap
© 2026 Ashwin Sharma · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture